Trial Profile
A Multi-Center Evaluation of the Long-Term Safety and Efficacy of Spark-sponsored Gene Therapies in Males With Hemophilia A
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Dirloctocogene samoparvovec (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Therapeutic Use
- Sponsors NeuroRX; Spark Therapeutics
- 19 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 21 Feb 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2032.
- 21 Feb 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2032.